Nicholas J. Connors

Learn More
Given the current epidemic of harmful consequences from prescription opioids and heroin in the USA including 28,647 deaths due to opioids in 2014, naloxone has received widespread attention for use in hospital, prehospital, and bystander settings [1–3]. While naloxone can be a highly effective reversal agent for opioid poisoning, there appears to be a(More)
Opioid abuse and opioid overdose deaths have increased significantly over the past decade. Naloxone is a potentially life-saving medication that can reverse opioid-induced respiratory depression, though precipitated opioid withdrawal can pose acute risks to the patient and medical personnel. The optimal naloxone dose is unclear and few studies address this(More)
While we read with great interest the recent report concerning the reversal of dabigatran-induced coagu-lopathy [1], we are concerned that methodological issues limit the validity of the authors' conclusions. Firstly, it is unclear why a porcine model was utilized. Although there is clinical relevance for testing reversal agents in a trauma model, all(More)
High-dose methotrexate (MTX) can produce acute kidney injury, impairing MTX elimination. Continuous venovenous hemofiltration (CVVH) may enhance elimination in this setting, although its use is largely unstudied. A 79-year-old man received IV MTX for central nervous system lymphoma, and over a 34-h period his serum creatinine increased from 1.09 to 2.24(More)
Atropine is the mainstay of therapy in organophosphate (OP) toxicity, though research and consensus on dosing is lacking. In 2004, as reported by Eddleston et al. (J Toxicol Clin Toxicol 42(6):865-75, 2004), they noted variation in recommended regimens. We assessed revisions of original references, additional citations, and electronic sources to determine(More)
  • 1